Eli Lilly and Company (LLY) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 May, 2026Opening remarks and agenda
The meeting was held virtually to ensure broad shareholder participation and followed a set agenda as outlined in the notice and slide presentation.
Shareholders were reminded of meeting conduct rules and the process for submitting questions.
The meeting was called to order with a quorum present, allowing official business to proceed.
Board and executive committee updates
Four directors were nominated for election to serve until 2029, with their qualifications detailed in the proxy statement.
The board recommended voting for all director nominees and management proposals.
Shareholder proposals
Proposal 6 called for an independent board chair, citing legal and governance risks, insider ownership, and industry trends.
Proposal 7 requested annual disclosure of lobbying expenditures, including indirect and dark money payments, to improve transparency.
The board recommended voting against both shareholder proposals.
Latest events from Eli Lilly and Company
- Q1 2026 revenue up 56% to $19.8B, EPS up 156%, with raised guidance and major product milestones.LLY
Q1 20261 May 2026 - Key votes include director elections, governance reforms, and executive pay approval.LLY
Proxy filing20 Mar 2026 - Record results, governance reforms, and strong board oversight define this year's proxy.LLY
Proxy filing20 Mar 2026 - Record 2025 results, major governance reforms, and expanded access initiatives drive shareholder focus.LLY
Proxy Filing6 Mar 2026 - Orforglipron nears U.S. launch as portfolio and global expansion drive future growth.LLY
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Q4 2025 revenue rose 43% to $19.3B; 2026 guidance set at $80–$83B revenue.LLY
Q4 20254 Feb 2026 - Q2 revenue up 36% with raised guidance, strong incretin sales, and major pipeline progress.LLY
Q2 20242 Feb 2026 - Manufacturing expansion, pipeline progress, and broadening access drive near-term growth.LLY
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Oncology pipeline and revenue surge with new modalities, pivotal trials, and strong brand growth.LLY
Status Update31 Jan 2026